Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts

References

• Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist14, 706–716 (2009).
   PubMed Web of Science ®Google Scholar
• Engeland A, Haldorsen T, Tretli S et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival study. A collaborative study of the Nordic Cancer Registries. APMIS49(Suppl.), 1–161 (1995).
   Google Scholar
• Herzog TJ, Herrin VE. Medical treatment for relapsed epithelial ovarian cancer. UpToDate, October 8 (2010).
   Google Scholar
• Markman M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J.15, 105–109 (2009).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Alberts D, Birrer M et al. Current challenges and future directions in the management of ovarian cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clin. Ovarian Cancer3, 81–97 (2010).
   Google Scholar
• Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol.9, 389–393 (1991).
   PubMed Web of Science ®Google Scholar
• Salani R, Santillan A, Zahurak ML et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer109, 685–691 (2007).
   PubMed Web of Science ®Google Scholar
• Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent platinum-sensitive epithelial ovarian carcinoma. Cancer106, 1933–1939 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase-III randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Bois AD, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin in gynecologic malignancies: a prospective Phase-II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol.107, 518–525 (2007).
   PubMedGoogle Scholar
• Strother R, Matei D. Pegylated liposomal doxorubicin in ovarian cancer. Ther. Clin. Risk Manag.5, 639–650 (2009).
   PubMedGoogle Scholar
• Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety24, 903–920 (2001).
   PubMedGoogle Scholar
• Allen TM. Lipsosomes. Drugs54(Suppl. 4), 8–14 (1997).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized Phase-III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Dezube BJ. Safety assessment: Doxil (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi’s sarcoma. In: Doxil Clinical Series. Gardiner-Caldwell SynerMed, NJ, USA, 1–8 (1996).
   Google Scholar
• Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety22, 263–302 (2000).
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching of exceeding cumulative doses of 500 mg/m2. Ann. Oncol.11, 1029–1033 (2000).
   PubMed Web of Science ®Google Scholar
• Uyar D, Kulp B, Peterson G et al. Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol. Oncol.94, 147–151 (2004).
   PubMed Web of Science ®Google Scholar
• Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy56, 108–111 (2010).
   PubMed Web of Science ®Google Scholar
• Kim RJ, Peterson G, Kulp B et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol. Oncol.97, 374–378 (2005).
   PubMedGoogle Scholar
• Steppan I, Reimer D, Sevelda U et al. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin: an evaluation of the therapeutic index with special emphasis on cardiac toxicity. Chemotherapy55, 391–398 (2009).
   PubMedGoogle Scholar
• Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist10, 205–214 (2005).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol.28, 3107–3114 (2010).
   PubMed Web of Science ®Google Scholar
• Campos S, Penson R, Mays A et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol.81, 206–212 (2001).
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K et al. Phase-II trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and Fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol.78, 369–372 (2000).
   PubMed Web of Science ®Google Scholar
• Rose PG, Maxson JH, Fusco N et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol. Oncol.82, 323–328 (2001).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol.24, 4699–4707 (2006).
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Savarese A et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial. J. Clin. Oncol.27(18S), LBA5508 (2009).
   Google Scholar
• Pignata S, Scambia G, Savarese A et al. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer6, 202 (2006).
   PubMed Web of Science ®Google Scholar
• Gonclaves A, Braud AC, Viret F et al. Phase-I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res.23, 3543–3548 (2003).
   PubMedGoogle Scholar
• du Bois A, Burges A, Meier W et al. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective Phase-I/II study of the Arbeitsgeminschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann. Oncol.17, 93–96 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase-II trial. Ann. Oncol.18, 263–268 (2007).
   PubMed Web of Science ®Google Scholar
• Power P, Stuart G, Oza A et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a Phase-II study. Gynecol. Oncol.114, 410–414 (2009).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol. Oncol.108, 90–94 (2008).
   PubMed Web of Science ®Google Scholar
• du Bois A, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin in gynecologic malignancies: a prospective Phase-II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol.107, 518–525 (2007).
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Vorobiof DA, Slabber C et al. Phase-II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int. J. Gynecol. Cancer19, 1137–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Linardou H, Aravantinos G et al. A randomized Phase-II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study. BMC Med.8, 1–12 (2010).
   PubMedGoogle Scholar
• Pujada-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol.28, 3323–3329 (2010).
   PubMedGoogle Scholar
• Marth C, Alexandre J, Hanker L et al. Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients: treatment at recurrence and overall survival final analysis from CALYPSO Phase-III GCIG trial. J. Clin. Oncol.29, 15S (2011) (Abstract 5052).
   Google Scholar
• Holloway RW, Grendys EC, Lefebvre P et al. Tolerability, efficacy, and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine-carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systemic review. Oncologist15, 1073–1082 (2010).
   PubMed Web of Science ®Google Scholar
• Tobias D, Runowicz C, Mandeli J et al. A Phase-I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol.19, 392a (2000).
   Google Scholar
• D’Agostino G, Ferrandina G, Garganese G et al. Phase-I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology62, 110–114 (2002).
   PubMed Web of Science ®Google Scholar
• Holloway RW, Finkler NJ, Nye L et al. Pegylated liposomal doxorubicin and gemcitabine therapy for recurrent ovarian cancer: updated analysis of outcomes and long-term survival. Gynecol. Oncol.101(Suppl. 1), A275 (2006).
   Google Scholar
• Ferrandina G, Paris I, Ludovisi M et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol. Oncol.98, 267–273 (2005).
   PubMed Web of Science ®Google Scholar
• Mirza MR, Lund B, Lindegaard JC et al. A Phase-II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Gynecol. Oncol.119, 26–31 (2010).
   PubMedGoogle Scholar
• Nicoletto MO, Falci C, Pianalto D et al. Phase-II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol. Oncol.100, 318–323 (2006).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB et al. Final survival results of the randomized Phase-III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. J. Clin. Oncol.29, 15S (2011) (Abstract 5046).
   Google Scholar
• Kaye S, Kaufman B, Lubinski J et al. Phase-II study of the oral PARP inhibitor olaparib (AZD 2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann. Oncol.21, S8 (2010) (Abstract 9710).
   Google Scholar
• del Carmen MG. Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, Fallopian tube, or primary peritoneal cancers: results of a Phase-II study. J. Clin. Oncol.29, 15S (2011) (Abstract 5061).
   Google Scholar
• Campos S, Ghosh S. A current review of target therapeutics for ovarian cancer. J. Oncol.2010, 1–11 (2010).
   Google Scholar
• Jelovac D, Armstrong DK, Weil SC et al. Phase-I study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer. J. Clin. Oncol.29, 15S (2011) (Abstract 5056).
   Google Scholar
• Ongusaha PP, Kwak JC, Zwible AJ et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res.64, 5283–5290 (2004).
   PubMed Web of Science ®Google Scholar
• Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist4, 87–94 (1999).
   PubMedGoogle Scholar
• Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 Phase III randomized trial. Ann. Oncol.22, 39–48 (2011).
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Konner JA, Bell-McGuinn KM et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann. Oncol.22, 1127–1132 (2011).
   PubMed Web of Science ®Google Scholar
• Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol.22, 1346–1352 (2011).
   PubMed Web of Science ®Google Scholar
• Tan DS, Rothermundt C, Thomas K et al. ‘BRCAness’ syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol.26, 5530–5536 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolleto MO, Bertorelle R, Borgato L et al. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer. Int. J. Gynecol. Cancer19, 1022–1028 (2009).
   PubMedGoogle Scholar